|Bid||106.47 x 800|
|Ask||108.80 x 1300|
|Day's Range||102.39 - 110.50|
|52 Week Range||95.50 - 188.99|
|Beta (5Y Monthly)||0.18|
|PE Ratio (TTM)||5.34|
|Earnings Date||Nov 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jun 02, 2022|
|1y Target Est||161.76|
Subscribe to Yahoo Finance Plus to view Fair Value for BNTX
BioNTech (NASDAQ: BNTX) has turned in a dismal performance so far this year. The average analysts' price target reflects an upside potential of 56%. Granted, not every analyst is all that bullish about BioNTech.
The fight against COVID-19 isn't over yet, and the two companies remain very much in the battle.
Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with Pfizer.